Loretta Lazzarato

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1005564/loretta-lazzarato-publications-by-year.pdf
Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

71 papers	1,840 citations	23 h-index	41 g-index
77 ext. papers	2,105 ext. citations	5.6 avg, IF	4.14 L-index

#	Paper	IF	Citations
71	Cryo-EM structures of staphylococcal IsdB bound to human hemoglobin reveal the process of heme extraction.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2116708119	11.5	1
70	Galactosylated Prodrugs: A Strategy to Improve the Profile of Nonsteroidal Anti-Inflammatory Drugs. *Pharmaceuticals*, **2022**, 15, 552	5.2	0
69	Tuning NO release of organelle-targeted furoxan derivatives and their cytotoxicity against lung cancer cells. *Bioorganic Chemistry*, **2021**, 111, 104911	5.1	3
68	A generator of peroxynitrite activatable with red light. *Chemical Science*, **2021**, 12, 4740-4746	9.4	1
67	NO release regulated by doxorubicin as the green light-harvesting antenna. *Chemical Communications*, **2020**, 56, 6332-6335	5.8	2
66	DNA-Targeted NO Release Photoregulated by Green Light. *Chemistry - A European Journal*, **2020**, 26, 13627-13633	4.8	1
65	Enhancing doxorubicin anticancer activity with a novel polymeric platform photoreleasing nitric oxide. *Biomaterials Science*, **2020**, 8, 1329-1344	7.4	10
64	Can We Exploit β-Lactamases Intrinsic Dynamics for Designing More Effective Inhibitors?. *Antibiotics*, **2020**, 9,	4.9	2
63	Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. *Drug Resistance Updates*, **2020**, 50, 100682	23.2	72
62	Paracetamol-Galactose Conjugate: A Novel Prodrug for an Old Analgesic Drug. *Molecular Pharmaceutics*, **2019**, 16, 4181-4189	5.6	5
61	Fluorescent Nitric Oxide Photodonors Based on BODIPY and Rhodamine Antennae. *Chemistry - A European Journal*, **2019**, 25, 11080-11084	4.8	18
60	Methotrexate-Loaded Solid Lipid Nanoparticles: Protein Functionalization to Improve Brain Biodistribution. *Pharmaceutics*, **2019**, 11,	6.4	25
59	Combination of PDT and NOPDT with a Tailored BODIPY Derivative. *Antioxidants*, **2019**, 8,	7.1	5
58	Design, Biological Evaluation, and Molecular Modeling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-Glycoprotein Ligand Overcoming Multidrug Resistance in Cancer Stem Cells. *Journal of Medicinal Chemistry*, **2019**, 62, 974-986	8.3	13
57	A molecular hybrid producing simultaneously singlet oxygen and nitric oxide by single photon excitation with green light. *Bioorganic Chemistry*, **2019**, 85, 18-22	5.1	15
56	Tuning the Hydrophobicity of a Mitochondria-Targeted NO Photodonor. *ChemMedChem*, **2018**, 13, 1238-1245	3.7	5
55	Mitochondrial Delivery of Phenol Substructure Triggers Mitochondrial Depolarization and Apoptosis of Cancer Cells. *Frontiers in Pharmacology*, **2018**, 9, 580	5.6	16

54	Aceclofenac-Galactose Conjugate: Design, Synthesis, Characterization, and Pharmacological and Toxicological Evaluations. *Molecular Pharmaceutics*, **2018**, 15, 3101-3110	5.6	7
53	Anti-Pseudomonas activity of 3-nitro-4-phenylfuroxan. *Microbiology (United Kingdom)*, **2018**, 164, 1557-1566	2.6	4
52	Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors. *European Journal of Medicinal Chemistry*, **2018**, 144, 612-625	6.8	13
51	A Molecular Hybrid for Mitochondria-Targeted NO Photodelivery. *ChemMedChem*, **2018**, 13, 87-96	3.7	10
50	Galactosylated Pro-Drug of Ursodeoxycholic Acid: Design, Synthesis, Characterization, and Pharmacological Effects in a Rat Model of Estrogen-Induced Cholestasis. *Molecular Pharmaceutics*, **2018**, 15, 21-30	5.6	8
49	Furoxan Nitric Oxide Donors Disperse Pseudomonas aeruginosa Biofilms, Accelerate Growth, and Repress Pyoverdine Production. *ACS Chemical Biology*, **2017**, 12, 2097-2106	4.9	14
48	A Nonmetal-Containing Nitric Oxide Donor Activated with Single-Photon Green Light. *Chemistry - A European Journal*, **2017**, 23, 9026-9029	4.8	22
47	New furoxan derivatives for the treatment of ocular hypertension. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 479-483	2.9	5
46	Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity. *Journal of Medicinal Chemistry*, **2017**, 60, 8647-8660	8.3	29
45	-Dinitroalkyl Benzenes: A Novel Class of IOP-Lowering Agents for the Treatment of Ocular Hypertension. *ACS Medicinal Chemistry Letters*, **2017**, 8, 1054-1059	4.3	3
44	Structure-Activity Relationship Studies on Tetrahydroisoquinoline Derivatives: [4Ψ(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Rise to Potent and Selective Ligands of P-glycoprotein. *Journal of Medicinal Chemistry*, **2016**, 59, 6729-38	8.3	17
43	Light-Tunable Generation of Singlet Oxygen and Nitric Oxide with a Bichromophoric Molecular Hybrid: a Bimodal Approach to Killing Cancer Cells. *ChemMedChem*, **2016**, 11, 1371-9	3.7	22
42	A Potent and Selective P-gp Modulator for Altering Multidrug Resistance Due to Pump Overexpression. *ChemMedChem*, **2016**, 11, 374-6	3.7	11
41	H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance. *Journal of Medicinal Chemistry*, **2016**, 59, 4881-9	8.3	35
40	Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis. *European Journal of Medicinal Chemistry*, **2016**, 123, 523-531	6.8	48
39	A nitric oxide-donor furoxan moiety improves the efficacy of edaravone against early renal dysfunction and injury evoked by ischemia/reperfusion. *Oxidative Medicine and Cellular Longevity*, **2015**, 2015, 804659	6.7	18
38	Furazan and furoxan sulfonamides are strong carbonic anhydrase inhibitors and potential antiglaucoma agents. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 3913-21	3.4	25
37	Doxorubicin-antioxidant co-drugs. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 5307-10	2.9	19

36	Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance. *Molecular Pharmaceutics*, **2013**, 10, 161-74	5.6	52
35	Water-soluble nitric-oxide-releasing acetylsalicylic acid (ASA) prodrugs. *ChemMedChem*, **2013**, 8, 1199-209	3.7	18
34	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor. *ACS Medicinal Chemistry Letters*, **2013**, 4, 994-9	4.3	36
33	A rapid screening for cytochrome P450 catalysis on new chemical entities: cytochrome P450 BM3 and 1,2,5-oxadiazole derivatives. *Journal of Biomolecular Screening*, **2013**, 18, 211-8		6
32	Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 841-50	3.4	5
31	Synthesis and preliminary biological profile of new NO-donor tolbutamide analogues. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 3810-5	2.9	18
30	Designing multitarget anti-inflammatory agents: chemical modulation of the lumiracoxib structure toward dual thromboxane antagonists-COX-2 inhibitors. *ChemMedChem*, **2012**, 7, 1647-60	3.7	22
29	Searching for new NO-donor aspirin-like molecules: Furoxanylacyl derivatives of salicylic acid and related furazans. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 5852-60	3.4	25
28	New nitric oxide or hydrogen sulfide releasing aspirins. *Journal of Medicinal Chemistry*, **2011**, 54, 5478-84	8.3	28
27	Nitrooxyacyl derivatives of salicylic acid: aspirin-like molecules that covalently inactivate cyclooxygenase-1. *ChemMedChem*, **2011**, 6, 523-30	3.7	7
26	Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity. *ACS Medicinal Chemistry Letters*, **2011**, 2, 494-7	4.3	58
25	Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. *Journal of Experimental Medicine*, **2011**, 208, 1949-62	16.6	455
24	Physicochemical profile and in vitro permeation behavior of a new class of non-steroidal anti-inflammatory drug candidates. *European Journal of Pharmaceutical Sciences*, **2010**, 40, 217-21	5.1	1
23	Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs). *Bioorganic and Medicinal Chemistry*, **2010**, 18, 2428-38	3.4	21
22	Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth. *Chemico-Biological Interactions*, **2009**, 182, 183-90	5	17
21	Mechanistic insights into cyclooxygenase irreversible inactivation by aspirin. *ChemMedChem*, **2009**, 4, 939-45	3.7	30
20	Nitrooxymethyl-substituted analogues of celecoxib: synthesis and pharmacological characterization. *Chemistry and Biodiversity*, **2009**, 6, 369-79	2.5	14
19	(Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins. *Journal of Medicinal Chemistry*, **2009**, 52, 5058-68	8.3	30

18	Synthesis of some novel organic nitrates and comparative in vitro study of their vasodilator profile. *Journal of Medicinal Chemistry*, **2009**, 52, 4020-5	8.3	4
17	Searching for new NO-donor aspirin-like molecules: a new class of nitrooxy-acyl derivatives of salicylic acid. *Journal of Medicinal Chemistry*, **2008**, 51, 1894-903	8.3	34
16	Multitarget drugs: Focus on the NO-donor hybrid drugs. *Pure and Applied Chemistry*, **2008**, 80, 1693-1701	2.1	17
15	A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages. *Journal of Inflammation*, **2008**, 5, 12	6.7	27
14	Structure-antioxidant activity relationships in a series of NO-donor phenols. *ChemMedChem*, **2008**, 3, 1443-8	3.7	4
13	Novel antioxidant agents deriving from molecular combination of Vitamin C and NO-donor moieties. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 5199-206	3.4	15
12	NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties. *Journal of Medicinal Chemistry*, **2007**, 50, 1449-57	8.3	52
11	Amphiphilic NO-donor antioxidants. *ChemMedChem*, **2007**, 2, 234-40	3.7	2
10	NO-donor melatonin derivatives: synthesis and in vitro pharmacological characterization. *Journal of Pineal Research*, **2007**, 42, 371-85	10.4	12
9	Synthesis, chiral HPLC resolution and configuration assignment of 1-phenylglyceryl trinitrate stereomers. *Chirality*, **2006**, 18, 430-6	2.1	6
8	NO-donor phenols: a new class of products endowed with antioxidant and vasodilator properties. *Journal of Medicinal Chemistry*, **2006**, 49, 2886-97	8.3	43
7	Synthesis of NO-donor bisphosphonates and their in-vitro action on bone resorption. *Journal of Medicinal Chemistry*, **2005**, 48, 1322-9	8.3	22
6	Synthesis and antimalarial activities of some furoxan sulfones and related furazans. *European Journal of Medicinal Chemistry*, **2005**, 40, 1335-40	6.8	32
5	The furoxan system: design of selective nitric oxide (NO) donor inhibitors of COX-2 endowed with anti-aggregatory and vasodilating activities. *Chemistry and Biodiversity*, **2005**, 2, 886-900	2.5	28
4	Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 5971-4	2.9	23
3	Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin. *Journal of Medicinal Chemistry*, **2003**, 46, 747-54	8.3	84
2	Michael addition of Grignard reagents to tetraethyl ethenylidenebisphosphonate. *Journal of Organometallic Chemistry*, **2002**, 650, 77-83	2.3	24
1	A new class of ibuprofen derivatives with reduced gastrotoxicity. *Journal of Medicinal Chemistry*, **2001**, 44, 3463-8	8.3	63